This site is intended for health professionals only

Published on 6 December 2007

Share this story:
Twitter
LinkedIn

ACUITY study one-year follow-up results published

teaser

Follow-up results for the Acute Catheterisation and Urgent Intervention Triage strategY (ACUITY) study have been published in the Journal of the American Medical Association.

The prospective, randomised, open-label trial with one-year clinical follow-up involved 13,819 patients with moderate and high-risk ACS undergoing invasive treatment.

Patients were randomised to receive one of the following three treatment strategies:

* Either heparin plus GPI (n=4603) as the control group (either unfractionated heparin or enoxaparin was allowed in the control group);

* Bivalirudin plus GPI (n=4604) or;

* Bivalirudin monotherapy (n=4612).

The primary outcome assessed was of composite ischaemia (death, myocardial infarction, or unplanned revascularisation for ischaemia) at one year.

The following results were reported:

* Composite ischaemia at one year occurred in 15.4% of patients assigned to heparin plus GP IIb/IIIa inhibitors and 16.0% assigned to bivalirudin plus GP IIb/IIIa inhibitors (compared with heparin plus GP IIb/IIIa inhibitors, HR, 1.05; 95% CI, 0.95-1.16; P = 0.35), and 16.2% assigned to bivalirudin monotherapy (HR, 1.06; 95% CI, 0.95-1.17; P = 0.29).

* Mortality at one year occurred in an estimated 3.9% of patients assigned to heparin plus GP IIb/IIIa inhibitors, 3.9% assigned to bivalirudin plus GP IIb/IIIa inhibitors (HR, 0.99; 95% CI, 0.80-1.22; P = 0.92), and 3.8% assigned to bivalirudin monotherapy (HR, 0.96; 95% CI, 0.77-1.18; P = 0.67).

The researchers concluded that at one year, no statistically significant difference in rates of composite ischaemia or mortality among patients with moderate and high-risk ACS undergoing invasive treatment with the three therapies was found.

JAMA



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn